Your browser doesn't support javascript.
loading
A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome.
Srivastava, Siddharth; Jo, Booil; Zhang, Bo; Frazier, Thomas; Gallagher, Anne Snow; Peck, Fleming; Levin, April R; Mondal, Sangeeta; Li, Zetan; Filip-Dhima, Rajna; Geisel, Gregory; Dies, Kira A; Diplock, Amelia; Eng, Charis; Hanna, Rabi; Sahin, Mustafa; Hardan, Antonio.
Afiliação
  • Srivastava S; Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Jo B; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, USA.
  • Zhang B; Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Frazier T; Department of Psychology, John Carroll University, University Heights, OH 44118, USA.
  • Gallagher AS; Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Peck F; Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Levin AR; Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Mondal S; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, USA.
  • Li Z; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, USA.
  • Filip-Dhima R; Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Geisel G; Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Dies KA; Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Diplock A; Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Eng C; Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Hanna R; Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
  • Sahin M; Department of Pediatrics, Hematology, Oncology, Blood and Marrow Transplantation, Cleveland Clinic, Cleveland, OH 44195, USA.
  • Hardan A; Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Hum Mol Genet ; 31(20): 3393-3404, 2022 10 10.
Article em En | MEDLINE | ID: mdl-35594551
PTEN hamartoma tumor syndrome (PHTS) is a complex neurodevelopmental disorder characterized by mechanistic target of rapamycin (mTOR) overactivity. Limited data suggest that mTOR inhibitors may be therapeutic. No placebo-controlled studies have examined mTOR inhibition on cognition and behavior in humans with PHTS with/without autism. We conducted a 6-month phase II, randomized, double-blinded, placebo-controlled trial to examine the safety profile and efficacy of everolimus (4.5 mg/m2) in individuals (5-45 years) with PHTS. We measured several cognitive and behavioral outcomes, and electroencephalography (EEG) biomarkers. The primary endpoint was a neurocognitive composite derived from Stanford Binet-5 (SB-5) nonverbal working memory score, SB-5 verbal working memory, Conners' Continuous Performance Test hit reaction time and Purdue Pegboard Test score. Forty-six participants underwent 1:1 randomization: n = 24 (everolimus) and n = 22 (placebo). Gastrointestinal adverse events were more common in the everolimus group (P < 0.001). Changes in the primary endpoint between groups from baseline to Month 6 were not apparent (Cohen's d = -0.10, P = 0.518). However, several measures were associated with modest effect sizes (≥0.2) in the direction of improvement, including measures of nonverbal IQ, verbal learning, autism symptoms, motor skills, adaptive behavior and global improvement. There was a significant difference in EEG central alpha power (P = 0.049) and central beta power (P = 0.039) 6 months after everolimus treatment. Everolimus is well tolerated in PHTS; adverse events were similar to previous reports. The primary efficacy endpoint did not reveal improvement. Several secondary efficacy endpoints moved in the direction of improvement. EEG measurements indicate target engagement following 6 months of daily oral everolimus. Trial Registration Information: ClinicalTrials.gov NCT02991807 Classification of Evidence: I.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtorno Autístico / Síndrome do Hamartoma Múltiplo Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtorno Autístico / Síndrome do Hamartoma Múltiplo Idioma: En Ano de publicação: 2022 Tipo de documento: Article